Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. - Wikidata - wikimedia - TriplyDB

Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.

Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.

http://www.wikidata.org/entity/Q35764706

about

The Role of AGE/RAGE Signaling in Diabetes-Mediated Vascular Calcification Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice Advanced glycation: an important pathological event in diabetic and age related ocular disease Oxidative stress and diabetic complications Molecular mechanisms of diabetic vascular complications Deletion of hemojuvelin, an iron-regulatory protein, in mice results in abnormal angiogenesis and vasculogenesis in retina along with reactive gliosis.Multiplex analysis of age-related protein and lipid modifications in human Bruch's membrane Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function.Comparison of serum glycosylated hemoglobin levels in patients with diabetic cystoid macular edema with and without serous macular detachment.Advanced glycation end products of bovine serum albumin-induced endothelial-to-mesenchymal transition in cultured human and monkey endothelial cells via protein kinase B signaling cascades.Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.α-Melanocyte-stimulating hormone protects retinal vascular endothelial cells from oxidative stress and apoptosis in a rat model of diabetes Ocular rigidity and outflow facility in nonproliferative diabetic retinopathy Pericyte-derived sphingosine 1-phosphate induces the expression of adhesion proteins and modulates the retinal endothelial cell barrier.Role of advanced glycation end products in cardiovascular disease.Vasoregression: A Shared Vascular Pathology Underlying Macrovascular And Microvascular Pathologies?Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers.Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis.Alterations of retinal vasculature in cystathionine-Beta-synthase mutant mice, a model of hyperhomocysteinemia AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice.Diabetes downregulates large-conductance Ca2+-activated potassium beta 1 channel subunit in retinal arteriolar smooth muscle Cellular signaling and potential new treatment targets in diabetic retinopathy.Oxidative stress in diabetes: implications for vascular and other complications.Advanced glycation end products increase retinal vascular endothelial growth factor expression.Deletion of thioredoxin-interacting protein preserves retinal neuronal function by preventing inflammation and vascular injury.Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.Dietary hyperglycemia, glycemic index and metabolic retinal diseases.Diabetes-related adduct formation and retinopathy.Advanced glycation end products and diabetic retinopathy.Molecular mechanisms of diabetic retinopathy: potential therapeutic targets.Advanced glycation End-products (AGEs): an emerging concern for processed food industries.Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy.Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.Neurovascular protective effect of FeTPPs in N-methyl-D-aspartate model: similarities to diabetes.Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes.Role of interleukin-1beta in the pathogenesis of diabetic retinopathy.Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products.Advanced Glycation Endproducts Are Increased in the Animal Model of Multiple Sclerosis but Cannot Be Reduced by Pyridoxamine Treatment or Glyoxalase 1 Overexpression.

P2860

Q26740003-F26F77D3-876A-4C14-A504-15B28BCECF42 Q28344139-A3282041-7CDE-4BCB-9798-CA0EF0F414B5 Q28365776-9FB19CEE-BB05-4811-94BE-9B591A8212D5 Q29615423-6DDC1C91-F8EB-4820-9E50-659B6592FCCE Q33558421-C00E644B-A01B-4C55-A7CD-79F6E71297D2 Q33739124-F3E72B87-69D0-406D-8FE3-C7F357255032 Q34352853-D6FD21CE-CAE9-4073-90E0-C9F05DF5C52D Q34355343-F00ACBB1-1BE5-49A6-896D-4B13FF0BB5F9 Q34356158-0E1DD5A0-6ADF-4979-A94A-AD387E0E2261 Q34410712-022BBC47-55FF-43F8-AC7A-130F4009C024 Q34758061-EA827ACE-8D95-4D41-BAED-628D1E2E3755 Q35138684-38428774-642B-4A2D-9C18-9FF80192413E Q35543684-835485E2-93B0-47D4-8ADB-89AF8A1EC13A Q35575592-1DD5964B-D4D1-4010-A99D-E7DE8BE431B4 Q35929112-5AEBFC83-99C9-4F1C-BA1B-262F6C2DBD0D Q36384149-28B5DE79-DCC0-4DAE-AD0C-4C40844099B7 Q36438245-2FB3C83A-3B7B-4875-B061-41019E0D613E Q36438378-05DBF431-3D74-4D21-AF73-A9D80B21D07F Q36587668-5B18DF9C-6E55-4AA7-81D4-E7A14C737D82 Q36844673-0F672397-38EE-4D11-A9E3-8B641B0DCF94 Q37000197-656A09A4-CFB7-47D5-A1BF-100326CBBC85 Q37089750-E7DAC132-3CA8-45EC-B7D4-65A754B5273E Q37375332-FB38EB51-652F-4696-8573-F0798A1D4C45 Q37379211-CE4FF1C1-A140-4E1A-9549-A4B3AE47A77B Q37635278-BDCC94A2-58EC-4C10-B553-3777383CE687 Q37690997-3A75F635-931C-4E9C-864D-FB2770F67936 Q37733102-1A7B3B98-5CEB-4EA2-855F-BCF1D7EBCFD4 Q38070160-D39E2787-82C4-4314-A148-A3629ABA412E Q38193463-AB2B32C9-35C5-4BD9-AFAF-1CA59A51276B Q38463463-1F4298C2-4B33-4BE0-9994-0011D41C98EA Q38647079-6B3663D4-D929-445E-854F-0901E62C5F5A Q38806774-936F2734-328F-4548-8A05-A0DD89E1CA27 Q40477757-72FB864E-9E50-49A7-A011-646DBEF2EC79 Q41789363-46A7E8EB-7DEE-4C75-8D02-2795EEDC04C3 Q42470643-3D95B3BC-D764-4CED-A840-7DD8FB5E064B Q42767408-E080984D-328C-4649-998B-E882E3287517 Q43007582-A68895D4-809C-4757-8962-5C0773EB228E Q45151232-31593B6F-FDDD-4147-8E26-340608DF1B99 Q52716248-68051B23-D8A4-4ABC-A4AB-16AF58E9C0D8

P2860

Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.

http://www.wikidata.org/entity/Q35764706

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

1997年论文

@zh

1997年论文

@zh-cn

name

Advanced glycation end product ...... betic and of AGE-infused rats.

@ast

Advanced glycation end product ...... betic and of AGE-infused rats.

@en

type

label

Advanced glycation end product ...... betic and of AGE-infused rats.

@ast

Advanced glycation end product ...... betic and of AGE-infused rats.

@en

prefLabel

Advanced glycation end product ...... betic and of AGE-infused rats.

@ast

Advanced glycation end product ...... betic and of AGE-infused rats.

@en

P1433

Q35764706-B32DFEAD-A1B4-402B-8E42-999532AACC3A

P1476

Q35764706-5113B57B-E38C-42E8-A290-BA937EECC319

P2093

Q35764706-3549D8AF-39CA-4D95-8373-93C2CE799522

Q35764706-3CF61305-C4CA-4905-88EF-F143F086F3BB

Q35764706-71B7BD52-40FB-48F1-89D1-29697093531A

Q35764706-8AAB75BB-DECA-4F70-8F90-64A833E5B722

Q35764706-8D2E33F5-B737-4039-ABD1-7DB8B24EC888

Q35764706-E902558A-0973-42B7-8031-D06598DA9D43

P2860

Q35764706-085362D1-2073-4AA1-A0F8-429BB1581CF9

Q35764706-09A1BF8A-9C60-4BA0-A749-521E5699CBA2

Q35764706-18F04FE9-D698-4496-9950-1721A304C23A

Q35764706-27A3923A-AF7C-42F8-AFC5-0F68B6685923

Q35764706-281AA954-1BF3-43A3-98DE-2BE9B2573696

Q35764706-2B34031E-B7C5-4736-AE95-B798D6EFE590

Q35764706-45E5ABB7-F356-4F76-9BDC-FEA841701874

Q35764706-45FB4249-D809-4E7B-A67B-8641D95336CF

Q35764706-4EC87B07-18FC-441A-92FA-392E9FAD72CA

Q35764706-4F826AB4-ABA2-4A8D-AE47-F9C481A862E8

P304

Q35764706-02B033B4-A894-4F2B-9BBF-73D6AF375C2F

P31

Q35764706-9CEB8BAC-C941-4FD1-A38B-7F911034B166

P407

Q35764706-86015AD5-66E7-4CB9-B123-197C95B13C9C

P433

Q35764706-C0C5F89A-E4BB-4130-B953-351FDD1705B9

P478

Q35764706-AC58E106-01F3-4F90-8F26-EE7FA0319E0D

P577

Q35764706-C00891BE-95C5-492B-886F-0150FAED3CC8

P698

Q35764706-50E346C1-07E2-4054-9B79-A886B1B4E094

P932

Q35764706-65DA798F-4313-4BFD-BF8D-00F56F16505D

P1433

The American Journal of Pathology

P1476

Advanced glycation end product ...... betic and of AGE-infused rats.

@en

P2093

A W Stitt

http://www.w3.org/2001/XMLSchema#string

D B Archer

http://www.w3.org/2001/XMLSchema#string

H Vlassara

http://www.w3.org/2001/XMLSchema#string

R Bucala

http://www.w3.org/2001/XMLSchema#string

T A Gardiner

http://www.w3.org/2001/XMLSchema#string

Y M Li

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation of cDNAs encoding a substrate for protein kinase C: nucleotide sequence and chromosomal mapping of the gene for a human 80K protein

Accelerated age-related browning of human collagen in diabetes mellitus

Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.

Advanced glycosylation: chemistry, biology, and implications for diabetes and aging.

Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues.

Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus.

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties.

P304

523-531

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

150

http://www.w3.org/2001/XMLSchema#string

P577

1997-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9033268

http://www.w3.org/2001/XMLSchema#string

P932

1858286

http://www.w3.org/2001/XMLSchema#string